# An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

> **NCT03704077** · PHASE2 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Gastric Cancer
- Cancer of the Stomach
- Stomach Cancer
- Gastroesophageal Junction

## Interventions

- **BIOLOGICAL:** Relatlimab + Nivolumab
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Paclitaxel
- **DRUG:** Ramucirumab

## Key facts

- **NCT ID:** NCT03704077
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-10-31
- **Primary completion:** 2022-02-27
- **Final completion:** 2024-09-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Replaced it with another clinical trial
- **Last updated:** 2020-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03704077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03704077, "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03704077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*